Congress wades into Right To Try; Eisai unloads a facility to Biogen;

@FierceBiotech: Singapore's big biotech push yields its first clinical contender. Story | Follow @FierceBiotech

@JohnCFierce: Interesting data points coming up on Alzheimer's, a field that makes giddy enthusiasts out of virtually all biz journalists. #odd | Follow @JohnCFierce

> Three members of the U.S. Congress have introduced a so-called Right To Try bill, seeking to restrict the FDA from standing in the way of patients trying to get access to unapproved medicines. News

> Eisai is handing over a North Carolina manufacturing facility to partner Biogen ($BIIB), planning to transfer about 100 employees in the process. More

> Galderma won FDA approval for its latest acne medication, called Epiduo Forte. Item

Medical Device News

@FierceMedDev: Illumina launches new lab service for HiSeq X sequencing systems. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Malaysian government approves 11 med tech projects worth $120M+. Report | Follow @VarunSaxena2

@EmilyWFierce: Cardiologists weigh in on #FDA's device oversight and 21st Century Cures Act. NYT story | Follow @EmilyWFierce

> EU funds development of a photonic-laser point-of-care cancer Dx device. More

> FDA approves the first implantable, above-the-knee prosthesis. Story

Pharma News

@FiercePharma: PetCure Spots Booming Market For Radiosurgery in Pets With Cancer. FierceAnimalHealth article | Follow @FiercePharma

@CarlyHFierce: Endo whistleblower nabs $33.6M from feds for 'extraordinary' work in FCA suit. Story | Follow @CarlyHFierce

> Valeant grabs a Middle Eastern foothold with $800M pact for Egypt's Amoun. More

> Gilead pushes some patients out of assistance program as it fights restrictive insurers. Story

> Pharma needs to get into digital health data game to stay competitive, study says. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.